The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors

Julia Lai‐Kwon; Chloe Khoo; Serigne Lo; Donna Milne; Mustafa Abdi Mohamed; Jeanette Raleigh; Kortnye Smith; Karolina Lisy; Shahneen Sandhu; Michael Jefford

doi:10.1007/s11764-019-00770-0

Related publications

Article2018

The survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors

Julia Lai‐Kwon, Christine Khoo, Serigne Lo, Donna Milne, Mustafa Abdi Mohamed, Jeanette Raleigh, Kortnye Smith, Karolina Lisy, Shahneen Sandhu, Michael Jefford

Article2018

Survivorship experience for patients (pts) with metastatic melanoma (MM) on immunotherapy (IT).

Julia Elizabeth Lai-Kwon, Chloe Khoo, Serigne Lo, Donna Milne, Mustafa Abdi Mohamed, Jeanette Raleigh, Kortnye Smith, Shahneen Sandhu, Michael Jefford

Article2018

Survivorship experience for patients (pts) with metastatic melanoma (MM) on long-term targeted therapy (TT).

Chloe Khoo, Julia Elizabeth Lai-Kwon, Serigne Lo, Donna Milne, Mustafa Abdi Mohamed, Jeanette Raleigh, Kortnye Smith, Michael Jefford, Shahneen Sandhu

Article2015

Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with <scp>BRAF</scp> or combined <scp>BRAF</scp> and MEK inhibitors

Alexander M. Menzies, James S. Wilmott, Martin Drummond, Serigne Lo, Megan Lyle, Matthew Chan, John F. Thompson, Alex Guminski, Matteo S. Carlino, Richard A Scolyer, Richard Kefford, Georgina V. Long

Article2015

Predictive value of integrative epigenetic profiling in metastatic melanoma (MM) patients (p) treated with BRAF/MEK inhibitors (BMI) and chemotherapy (CT).

José Luís Manzano, Anna Martínez Cardús, María Teresa Fernández‐Figueras, Aram Boada, José Luis Cuadra‐Urteaga, SebastiÃÂ¡n MorÃÂ¡n, Cristina Bugés, María de los Llanos Gil, Laura Layos, Alberto Indacochea, Laia Martínez, Max Hardy, Iris Teruel, Eva Martinez‐Balibrea, Manel Esteller

The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors

Discussion(0)

Related publications

The survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors

Survivorship experience for patients (pts) with metastatic melanoma (MM) on immunotherapy (IT).

Survivorship experience for patients (pts) with metastatic melanoma (MM) on long-term targeted therapy (TT).

Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with <scp>BRAF</scp> or combined <scp>BRAF</scp> and MEK inhibitors

Predictive value of integrative epigenetic profiling in metastatic melanoma (MM) patients (p) treated with BRAF/MEK inhibitors (BMI) and chemotherapy (CT).